Lamivudine monoprophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants and second generation recombinant HBV vaccine is not effective. We studied the efficacy of 2 courses each of 3 double-doses (20 ug) of third generation recombinant pre-S containing vaccine (Sci-B-Vac TM ) in 20 patients on lamivudine prophylaxis at a median of 637 days (range, 390-2,666 days) after transplantation. At enrolment, all patients were seronegative for HBsAg, anti-HBs and HBVDNA (by qPCR). Lamivudine (100 mg/day) was continued throughout the study. Five patients (25%) responded to the first course and 5 additional patients responded after the second course (overall response rate 50%). The response rate was 88% in patients younger than 50 years old and 25% in older patients (p=0.02). The median peak anti-HBs titer was 153 mIU/mL with 6 responders having a titer > 100 mIU/mL and 7 sustained > 6 months. Among 7 previous nonresponders to second generation recombinant vaccine, 3 (44%) responded. At the end of the study, all patients remained seronegative for HBsAg. In conclusion, Sci-B-Vac TM is effective in about 50% of patients receiving lamividine prophylaxis and may prevent recurrence due to escape mutants.
Introduction
The results of liver transplantation for hepatitis B virus (HBV)-related liver disease has dramatically improved over the last decade. Passive immunoprophylaxis with hepatitis B immunoglobulin (HBIG) (1, 2) and anti-viral agents such as lamivudine (3, 4, 5) are both effective in preventing HBV reinfection after liver transplantation. The graft survival with lamivudine monoprophylaxis is comparable to that of long-term HBIG prophylaxis (4) but reinfection due to emergence of escape mutant with prolonged therapy is the major concern. Combining HBIG with lamivudine prophylaxis has proved to be extremely effective in reducing HBV reinfection to less than 10% (6) (7) (8) (9) (10) (11) (12) and this combination has been regarded by many as the preferred prophylactic strategy (13) . Nonetheless, the potential drawbacks of long-term HBIG continues to be an issue and the optimal dosage and duration of HBIG therapy remain unknown. Hence, attempts to develop less costly and more definitive means of prophylaxis against HBV reinfection continue.
Vaccination to confer active immunity for endogenous production of anti-HBs is theoretically a simpler, safer and cheaper prophylactic strategy than passive immunization using HBIG. We have previously proposed a strategy of combining active immunization with antiviral prophylaxis, and attempted HBV vaccination as an additional prophylactic measure to reduce the risk of emergence of escape mutants in patients receiving lamivudine prophylaxis after liver transplantation (14) . Unfortunately, 2 courses of an accelerated schedule of double-dose secondgeneration recombinant HBV vaccine had limited efficacy in this setting. In this study, we continue to explore this strategy and evaluated the efficacy of a more immunogenic thirdgeneration recombinant HBV vaccine containing S, pre-S1 and pre-S2 antigens.
Patients and methods
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Patients
Twenty liver transplant recipients who had undergone liver transplantation for chronic hepatitis B-related liver disease and had no evidence of HBV recurrence nor immunity at more than 12 months after transplantation were recruited at the outpatient clinic into the current study.
The baseline demographic, clinical and virologic characteristics of these patients are shown in None had coinfection with hepatitis delta virus or hepatitis C virus. Two patients had received lamivudine therapy (100 mg daily) for more than 12 months before transplantation and 8 for 1 month to 12 months. The remaining 10 patients had pretransplant lamivudine for less than 1 month. Lamivudine therapy was continued indefinitely after transplantation according to a protocol as described previously (5) and HBIG was not used at any stage.
We excluded patients who had received the transplant for less than 12 months, who had received other prophylaxis such as passive immunoprophylaxis with HBIG or add-on adefovir dipivoxil therapy, who were HBsAg-positive with or without viral breakthrough, or who remained positive for anti-HBs after transplantation. The median interval from transplantation to enrolment was 637 days (range, 390 to 2666 days). Thirteen (65%) patients had received liver transplant for 1-3 years and 7 (35 %) had the transplant more than 3 years ago. Eight patients had previously been enrolled in a study on vaccination using two courses of a double-dose reinforced schedule of second generation recombinant HBV vaccine (14) . Seven did not respond and only one developed a peak anti-HBs titer of 27 mIU/mL that disappeared rapidly. The last dose of Lo HBV 
Vaccination protocol
Patients enrolled in the study received a third generation recombinant hepatitis B vaccine (Sci-B-Vac TM , Bio-Technology General Ltd., Rehovot, Israel) produced in HBV transfected Chinese hamster ovary cells which secretes all 3 epitopes of the envelope proteins, namely S, pre-S1 and pre-S2. The schedule consisted of 2 courses each of 3 double-doses (20 μg) of vaccine administered by intramuscular injection into deltoid muscle at months 0, 1, and 2 and then months 6, 7, and 8 after enrolment.
Follow-up and response
The patients were followed at least monthly at the clinic and the anti-HBs titer was measured using a microparticle enzyme immunoassay (IMx AUSAB, Abbott Laboratories, Chicago, IL) before each dose of vaccine, and monthly for at least 6 months after the last dose of 
Results
Response to vaccination
Discussion
Recurrence due to emergence of escape mutant is common with long-term lamivudine prophylaxis after liver transplantation (3, 4) and additional prophylactic measure such as passive immunoprophylaxis has been recommended. On the other hand, lamivudine-resistant HBV mutant can now be effectively controlled with other anti-viral agents such as adefovir dipivoxil (15, 16) . As a result of the prohibitive cost of HBIG, we have adopted a strategy of anti viral prophylaxis using primary lamivudine with adefovir rescue with fairly good results in terms of graft and patient survival (16) . A recent study indicated that the cost-effectiveness of combination of lamivudine and HBIG is highly sensitive to the cost of HBIG (17) and when compared to a strategy of lamivudine with adefovir rescue, the incremental cost-effectiveness ratio of lamivudine with HBIG exceeds the threshold for cost-effectiveness even when a regimen of very low dose intramuscular HBIG was considered. Antiviral prophylaxis using lamivudine with adefovir rescue was found to be the more cost-effective option, though at a possible price of higher recurrence rate.
The current study shows that a strategy of combining active immunization to reduce the recurrence rate with anti-viral prophylaxis is feasible in a proportion of patients after liver transplantation for chronic hepatitis B. About half of post-transplant patients receiving lamivudine prophylaxis responded to 2 courses of a more immunogenic third-generation pre-S containing HBV vaccine, Sci-B-Vac TM . In a significant proportion of the responders, the ani-HBs titer was higher than 100 mIU/mL and the response was sustained for more than 6 months.
All early responders who responded to the first course had intense and sustained antibody response after the second course suggesting that a second course of vaccination is necessary and should be given even in the early responders. Whether additional courses of vaccine or boosters would enhance or prolong the humoral immune response remains to be defined by Lo HBV vaccination and lamivudine prophylaxis AJT-O-06-00718 9 further studies. Admittedly, the follow up period of the current study is relatively short and we assessed immunogenicity of the vaccine instead of its efficacy to prevent recurrence.
Nonetheless, this is the first report of the successful induction of active humoral immune response in a sizable proportion of patients on lamivudine prophylaxis after transplantation.
Anti-HBs response is protective against HBV infection and is likely to offer protection against the emergence of lamivudine-resistant mutant which is the major drawback of long term antiviral monoprophylaxis. The ultimate objective of this strategy, however, is to provide definitive protection against HBV reinfection. Before lamivudine prophylaxis can be discontinued, more studies are needed to provide proof on the complete clearance of HBV and the durability of the HBV immune response.
The results of the present study contrasted with our previous report in which 2 courses of a second-generation recombinant vaccine failed to induce active immunity in a similar setting (14) . In fact, 44% of previous non-responders in the last study responded to Sci-B-Vac TM , hence, confirming the enhanced immunogenicity of the third-generation vaccine. The vaccine contains glycosylated and nonglycosylated forms of all 3 epitopes of the envelope proteins absorbed to alum and has been shown to have an immunogenic advantage by eliciting a faster and more intense antibody response (18, 19) as well as a superior response rate in non-responders of second-generation yeast-derived vaccine (20) .
The question remains open why some patients respond to Sci-B-Vac TM while others do not. The response to vaccination was not related to the donor's HBV immunity status and was unlikely to be a secondary response of the adoptively transferred immunity from an HBV immune donor (21) . The relatively small number of study subjects limited the power of the current study but age was found to be a predictor of response and this is compatible with Lo HBV vaccination and lamivudine prophylaxis AJT-O-06-00718 10 previous findings on the effect of age on response to HBV vaccination in non-transplant setting (22, 23) . The favorable response rate of 88% in patients younger than 50 years of age in the current study indicates that these patients are likely to benefit from the vaccination and should receive at least 2 courses of the vaccine. For patients who were older, the response rate was low (25%) and an early non-response to the first course of vaccination would be predictive of a failure of active immunization.
Reported trials of active immunization to replace HBIG in patients receiving passive immunoprophylaxis included only patients who were at low risk for HBV reinfection based on a pretransplant non-replicative HBV status and a prolonged post-transplant recurrencefree period (24) (25) (26) (27) . On the other hand, the value of prevention depends on the risk of an event and the cost-effectiveness of any prophylactic measure against HBV refection increases with the risk of recurrence. Hence, in order to investigate the value of vaccination as an additional measure to prevent the emergence of lamivudine-resistant mutant, we did not exclude high-risk patients with active HBV replication before transplant who were most likely to benefit from the additional protection. All patients in the current study suffered from we have previously observed that about 40% of our patients on lamivudine prophylaxis developed anti-HBs spontaneously after transplantation which lasted for a median of about 7 months (21) . As a result of such distinct post-transplant serologic profile, the optimal time for active immunization for these patients would probably be at one year after transplant. It would be necessary to conduct a prospective study in which active immunization is included as part of the protocol for prophylaxis for all patients who are at risk.
In conclusion, 2 courses of double-dose third-generation recombinant pre-S containing HBV vaccine induce humural immune response in selected patients receiving lamivudine prophylaxis after liver transplantation. The additional protection may prevent the emergence of escape mutants and improve further the outcome of the strategy of lamivudine prophylaxis with adefovir rescue. More studies should be performed to identify the patients who would benefit most from active immunization and to increase the response rate by defining the optimal schedule and timing of vaccination.
Figure legend
Serial changes in anti-HBs titers after vaccination in 10 responders. * by bDNA assay (x 10 6 copies/ml; lowest detection limit, 0.7 x 10 6 copies/ml). 
